The weekly litigation news digest is live. Subscribe now
Use Of Riluzole Prodrugs To Treat Ataxias - EP3706739
The patent EP3706739 was granted to Biohaven Pharmaceutical Holding on Oct 16, 2024. The application was filed on Nov 11, 2018 under application number EP18876779A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3706739
- Application Number
- EP18876779A
- Filing Date
- Nov 11, 2018
- Status
- Granted And Under Opposition
- Sep 13, 2024
- Publication Date
- Oct 16, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Prodrugs of riluzole for treating spinocerebellar ataxia (SCA) comprising a riluzole molecule linked to a hydrophilic moiety, such as a carboxylic acid or ester group, to enhance solubility and bioavailability. The prodrugs are administered orally in a dosage of 17.5-200 mg/day, with a preferred dosage of 100-140 mg/day, and are effective in improving symptoms of SCA, including ataxia, dysarthria, and dysphagia, as measured by clinical rating scales such as the Scale for the Assessment and Rating of Ataxia (SARA).
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (29) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents